Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2018 (2018), Article ID 4010629, 15 pages
https://doi.org/10.1155/2018/4010629
Review Article

Therapeutic Potential of Thymoquinone in Glioblastoma Treatment: Targeting Major Gliomagenesis Signaling Pathways

1Department of Clinical Pharmacy and Pharmacology, University of Dhaka, Dhaka 1000, Bangladesh
2Department of Pharmaceutical Chemistry, University of Dhaka, Dhaka 1000, Bangladesh

Correspondence should be addressed to Muhammad Shahdaat Bin Sayeed; gro.liamthgirbluf@deeyas-nib.taadhahs-dammahum

Received 8 July 2017; Accepted 27 December 2017; Published 31 January 2018

Academic Editor: Sara Piccirillo

Copyright © 2018 Fabliha Ahmed Chowdhury et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. Szopa, T. A. Burley, G. Kramer-Marek, and W. Kaspera, “Diagnostic and therapeutic biomarkers in glioblastoma: current status and future perspectives,” BioMed Research International, vol. 2017, Article ID 8013575, 13 pages, 2017. View at Publisher · View at Google Scholar
  2. D. N. Louis, A. Perry, G. Reifenberger et al., “The 2016 world health organization classification of tumors of the central nervous system: a summary,” Acta Neuropathologica, vol. 131, no. 6, pp. 803–820, 2016. View at Publisher · View at Google Scholar
  3. Q. T. Ostrom, H. Gittleman, P. Farah et al., “CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006–2010,” Neuro-Oncology, vol. 15, supplement 2, pp. ii1–ii56, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. K. Anjum, B. I. Shagufta, S. Q. Abbas et al., “Current status and future therapeutic perspectives of glioblastoma multiforme (GBM) therapy: A review,” Biomedicine & Pharmacotherapy, vol. 92, pp. 681–689, 2017. View at Publisher · View at Google Scholar
  5. A. Sottoriva, I. Spiteri, S. G. M. Piccirillo et al., “Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 110, no. 10, pp. 4009–4014, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. T. R. Jue and K. L. McDonald, “The challenges associated with molecular targeted therapies for glioblastoma,” Journal of Neuro-Oncology, vol. 127, no. 3, pp. 427–434, 2016. View at Publisher · View at Google Scholar · View at Scopus
  7. Cancer Genome Atlas Research Network, “Comprehensive genomic characterization defines human glioblastoma genes and core pathways,” Nature, vol. 455, no. 7216, pp. 1061–1068, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. D. W. Parsons, “An integrated genomic analysis of human glioblastoma multiforme,” Science, vol. 321, no. 5897, pp. 1807–1812, 2008. View at Google Scholar
  9. H. Ohgaki and P. Kleihues, “Genetic alterations and signaling pathways in the evolution of gliomas,” Cancer Science, vol. 100, no. 12, pp. 2235–2241, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. K. E. Cahill, R. A. Morshed, and B. Yamini, “Nuclear factor-κB in glioblastoma: Insights into regulators and targeted therapy,” Neuro-Oncology, vol. 18, no. 3, pp. 329–339, 2016. View at Publisher · View at Google Scholar · View at Scopus
  11. C. W. Brennan, R. G. Verhaak, and A. McKenna, “The somatic genomic landscape of glioblastoma,” Cell, vol. 155, no. 2, pp. 462–477, 2013. View at Publisher · View at Google Scholar
  12. J. T. Huse and E. C. Holland, “Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma,” Nature Reviews Cancer, vol. 10, no. 5, pp. 319–331, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. Z. Piotrowska and L. V. Sequist, “Epidermal growth factor receptor-mutant lung cancer: New drugs, new resistance mechanisms, and future treatment options,” Cancer Journal, vol. 21, no. 5, pp. 371–377, 2015. View at Google Scholar · View at Scopus
  14. N. Chang, S. H. Ahn, D.-S. Kong, H. W. Lee, and D.-H. Nam, “The role of STAT3 in glioblastoma progression through dual influences on tumor cells and the immune microenvironment,” Molecular and Cellular Endocrinology, vol. 451, pp. 53–65, 2017. View at Publisher · View at Google Scholar · View at Scopus
  15. Z. G. Ouédraogo, J. Biau, J.-L. Kemeny, L. Morel, P. Verrelle, and E. Chautard, “Role of STAT3 in genesis and progression of human malignant gliomas,” Molecular Neurobiology, vol. 54, no. 8, pp. 5780–5797, 2017. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Mostofa, S. R. Punganuru, H. R. Madala, M. Al-Obaide, and K. S. Srivenugopal, “The process and regulatory components of inflammation in brain oncogenesis,” Biomolecules, vol. 7, no. 2, p. 34, 2017. View at Publisher · View at Google Scholar
  17. J. J. Miller and P. Y. Wen, “Emerging targeted therapies for glioma,” Expert Opinion on Emerging Drugs, vol. 21, no. 4, pp. 441–452, 2016. View at Publisher · View at Google Scholar · View at Scopus
  18. C. L. Arteaga, “Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia,” Seminars in Oncology, vol. 29, no. 5, pp. 3–9, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. D. A. Reardon, P. Y. Wen, and I. K. Mellinghoff, “Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges,” Neuro-Oncology, vol. 16, pp. viii7–viii13, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. Z. Duzgun, Z. Eroglu, and C. Biray Avci, “Role of mTOR in glioblastoma,” Gene, vol. 575, no. 2, pp. 187–190, 2016. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Sami and M. Karsy, “Targeting the PI3K/AKT/mTOR signaling pathway in glioblastoma: novel therapeutic agents and advances in understanding,” Tumor Biology, vol. 34, no. 4, pp. 1991–2002, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. D. J. Ma, E. Galanis, S. K. Anderson et al., “A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K,” Neuro-Oncology, vol. 17, no. 9, pp. 1261–1269, 2015. View at Publisher · View at Google Scholar · View at Scopus
  23. S. K. Carlsson, S. P. Brothers, and C. Wahlestedt, “Emerging treatment strategies for glioblastoma multiforme,” EMBO Molecular Medicine, vol. 6, no. 11, pp. 1359–1370, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Merlo, “Genes and pathways driving glioblastomas in humans and murine disease models,” Neurosurgical Review, vol. 26, no. 3, pp. 145–158, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. B. Sarcar, S. Kahali, A. H. Prabhu et al., “Targeting radiation-induced G 2 checkpoint activation with the wee-1 inhibitor MK-1775 in glioblastoma cell lines,” Molecular Cancer Therapeutics, vol. 10, no. 12, pp. 2405–2414, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. L. R. Werner, S. Huang, D. M. Francis et al., “Small molecule inhibition of MDM2-p53 interaction augments radiation response in human tumors,” Molecular Cancer Therapeutics, vol. 14, no. 9, pp. 1994–2003, 2015. View at Publisher · View at Google Scholar · View at Scopus
  27. T. Hundsberger, D. A. Reardon, and P. Y. Wen, “Angiogenesis inhibitors in tackling recurrent glioblastoma,” Expert Review of Anticancer Therapy, vol. 17, no. 6, pp. 507–515, 2017. View at Publisher · View at Google Scholar
  28. C. Lu-Emerson, D. G. Duda, K. E. Emblem et al., “Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with Glioblastoma,” Journal of Clinical Oncology, vol. 33, no. 10, pp. 1197–1213, 2015. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Kloepper, L. Riedemann, Z. Amoozgar et al., “Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival,” in Proceedings of the National Academy of Sciences, vol. 113, pp. 4476–4481, USA, 2016. View at Publisher · View at Google Scholar
  30. K. Ludwig and H. I. Kornblum, “Molecular markers in glioma,” Journal of Neuro-Oncology, vol. 134, no. 3, pp. 505–512, 2017. View at Publisher · View at Google Scholar · View at Scopus
  31. R. Velho-Pereira, A. Kumar, B. N. Pandey, A. G. Jagtap, and K. P. Mishra, “Radiosensitization in human breast carcinoma cells by thymoquinone: role of cell cycle and apoptosis,” Cell Biology International, vol. 35, no. 10, pp. 1025–1029, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. L. Dang, D. W. White, S. Gross et al., “Cancer-associated IDH1 mutations produce 2-hydroxyglutarate,” Nature, vol. 462, no. 7274, pp. 739–744, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. L. E. Jalbert, A. Elkhaled, J. J. Phillips et al., “Metabolic profiling of IDH mutation and malignant progression in infiltrating glioma,” Scientific Reports, vol. 7, Article ID 44792, 2017. View at Publisher · View at Google Scholar · View at Scopus
  34. L. Annovazzi, M. Mellai, and D. Schiffer, “Chemotherapeutic drugs: DNA damage and repair in glioblastoma,” Cancers, vol. 9, no. 6, p. 57, 2017. View at Publisher · View at Google Scholar
  35. T. Seymour, A. Nowak, and F. Kakulas, “Targeting aggressive cancer stem cells in glioblastoma,” Frontiers in Oncology, vol. 5, p. 159, 2015. View at Publisher · View at Google Scholar · View at Scopus
  36. L. Wei, Y.-K. Su, C.-M. Lin et al., “Preclinical investigation of ibrutinib, a Bruton's kinase tyrosine (Btk) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes,” Oncotarget , vol. 7, no. 43, pp. 69961–69975, 2016. View at Publisher · View at Google Scholar · View at Scopus
  37. R. Xu, F. Shimizu, K. Hovinga et al., “Molecular and clinical effects of notch inhibition in glioma patients: A phase 0/I trial,” Clinical Cancer Research, vol. 22, no. 19, pp. 4786–4796, 2016. View at Publisher · View at Google Scholar · View at Scopus
  38. C. Alifieris and D. T. Trafalis, “Glioblastoma multiforme: pathogenesis and treatment,” Pharmacology & Therapeutics, vol. 152, pp. 63–82, 2015. View at Publisher · View at Google Scholar · View at Scopus
  39. M. J. Salomi, S. C. Nair, and K. R. Panikkar, “Inhibitory effects of Nigella sativa and saffron (Crocus sativus) on chemical carcinogenesis in mice,” Nutrition and Cancer, vol. 16, no. 1, pp. 67–72, 1991. View at Publisher · View at Google Scholar · View at Scopus
  40. F. I. Al-Jenoobi, A. A. Al-Thukair, F. A. Abbas et al., “Effect of black seed on dextromethorphan O- and N-demethylation in human liver microsomes and healthy human subjects,” Drug Metabolism Letters, vol. 4, no. 1, pp. 51–55, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. F. R. Dehkordi and A. F. Kamkhah, “Antihypertensive effect of Nigella sativa seed extract in patients with mild hypertension,” Fundamental & Clinical Pharmacology, vol. 22, no. 4, pp. 447–452, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. M. S. B. Sayeed, M. Asaduzzaman, H. Morshed, M. M. Hossain, M. F. Kadir, and M. R. Rahman, “The effect of Nigella sativa Linn. seed on memory, attention and cognition in healthy human volunteers,” Journal of Ethnopharmacology, vol. 148, no. 3, pp. 780–786, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. M. S. Bin Sayeed, T. Shams, S. F. Hossain et al., “Nigella sativa L. seeds modulate mood, anxiety and cognition in healthy adolescent males,” Journal of Ethnopharmacology, vol. 152, no. 1, pp. 156–162, 2014. View at Publisher · View at Google Scholar · View at Scopus
  44. F. J. Marozzi Jr., A. B. Kocialski, and M. H. Malone, “Studies on the antihistaminic effects of thymoquinone, thymohydroquinone and quercetin.,” Arzneimittel-Forschung/Drug Research, vol. 20, no. 10, pp. 1574–1577, 1970. View at Google Scholar · View at Scopus
  45. M. El–Dakhakhny, “Studies on the chemical composition of Egyptian Nigella sativa L. Seed II1) The essential oil,” Planta Medica, vol. 11, no. 04, pp. 465–470, 1963. View at Publisher · View at Google Scholar
  46. H. U. Gali-Muhtasib, W. G. Abou Kheir, L. A. Kheir, N. Darwiche, and P. A. Crooks, “Molecular pathway for thymoquinone-induced cell-cycle arrest and apoptosis in neoplastic keratinocytes,” Anti-Cancer Drugs, vol. 15, no. 4, pp. 389–399, 2004. View at Publisher · View at Google Scholar · View at Scopus
  47. L. Peng, A. Liu, Y. Shen et al., “Antitumor and anti-angiogenesis effects of thymoquinone on osteosarcoma through the NF-kappaB pathway,” Oncology Reports, vol. 29, pp. 571–578, 2013. View at Google Scholar
  48. M. A. Khan, M. Tania, C. Wei et al., “Thymoquinone inhibits cancer metastasis by downregulating TWIST1 expression to reduce epithelial to mesenchymal transition,” Oncotarget , vol. 6, no. 23, pp. 19580–19591, 2015. View at Publisher · View at Google Scholar · View at Scopus
  49. J. Kundu, K.-S. Chun, O. I. Aruoma, and J. K. Kundu, “Mechanistic perspectives on cancer chemoprevention/chemotherapeutic effects of thymoquinone,” Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, vol. 768, no. C, pp. 22–34, 2014. View at Publisher · View at Google Scholar · View at Scopus
  50. L. Zhang, Y. Bai, and Y. Yang, “Thymoquinone chemosensitizes colon cancer cells through inhibition of NF-κB,” Oncology Letters, vol. 12, no. 4, pp. 2840–2845, 2016. View at Publisher · View at Google Scholar · View at Scopus
  51. D. Hanahan and R. A. Weinberg, “Hallmarks of cancer: the next generation,” Cell, vol. 144, no. 5, pp. 646–674, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. A. Omuro and L. M. DeAngelis, “Glioblastoma and other malignant gliomas: A clinical review,” Journal of the American Medical Association, vol. 310, no. 17, pp. 1842–1850, 2013. View at Publisher · View at Google Scholar · View at Scopus
  53. K. Aldape, G. Zadeh, S. Mansouri, G. Reifenberger, and A. von Deimling, “Glioblastoma: pathology, molecular mechanisms and markers,” Acta Neuropathologica, vol. 129, no. 6, pp. 829–848, 2015. View at Publisher · View at Google Scholar
  54. H. P. Ellis, M. Greenslade, B. Powell, I. Spiteri, A. Sottoriva, and K. M. Kurian, “Current challenges in glioblastoma: Intratumour heterogeneity, residual disease, and models to predict disease recurrence,” Frontiers in Oncology, vol. 5, article no. 251, 2015. View at Publisher · View at Google Scholar · View at Scopus
  55. O. O. Kanu, A. Mehta, C. Di et al., “Glioblastoma multiforme: a review of therapeutic targets,” Expert Opinion on Therapeutic Targets, vol. 13, no. 6, pp. 701–718, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. J. H. Kang and C. Adamson, “Novel chemotherapeutics and other therapies for treating high-grade glioma,” Expert Opinion on Investigational Drugs, vol. 24, no. 10, pp. 1361–1379, 2015. View at Publisher · View at Google Scholar · View at Scopus
  57. A. F. Majdalawieh, M. W. Fayyad, and G. K. Nasrallah, “Anti-cancer properties and mechanisms of action of thymoquinone, the major active ingredient of Nigella sativa,” Critical Reviews in Food Science and Nutrition, vol. 57, no. 18, pp. 3911–3928, 2016. View at Publisher · View at Google Scholar
  58. M. Asaduzzaman Khan, M. Tania, S. Fu, and J. Fu, “Thymoquinone, as an anticancer molecule: from basic research to clinical investigation,” Oncotarget, vol. 2017, pp. 51907–51919, 2017. View at Publisher · View at Google Scholar
  59. A. H. Rahmani, M. A. Alzohairy, M. A. Khan, and S. M. Aly, “Therapeutic implications of black seed and its constituent thymoquinone,” Evidence-Based Complementary and Alternative Medicine, vol. 2014, Article ID 724658, 13 pages, 2014. View at Publisher · View at Google Scholar
  60. A. Mostofa, M. K. Hossain, D. Basak, and M. S. Bin Sayeed, “Thymoquinone as a Potential Adjuvant Therapy for Cancer Treatment: Evidence from Preclinical Studies,” Frontiers in Pharmacology, vol. 8, 2017. View at Publisher · View at Google Scholar
  61. M. Nakada, D. Kita, T. Watanabe et al., “Aberrant signaling pathways in Glioma,” Cancers, vol. 3, no. 3, pp. 3242–3278, 2011. View at Publisher · View at Google Scholar · View at Scopus
  62. B. B. Friday and A. A. Adjei, “Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy,” Clinical Cancer Research, vol. 14, no. 2, pp. 342–346, 2008. View at Publisher · View at Google Scholar · View at Scopus
  63. A. B. Heimberger, R. Hlatky, D. Suki et al., “Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients,” Clinical Cancer Research, vol. 11, no. 4, pp. 1462–1466, 2005. View at Publisher · View at Google Scholar · View at Scopus
  64. T. P. Fleming, A. Saxena, W. C. Clark et al., “Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors,” Cancer Research, vol. 52, no. 16, pp. 4550–4553, 1992. View at Google Scholar · View at Scopus
  65. M. S. Ahluwalia, J. D. Groot, W. M. Liu, and C. L. Gladson, “Targeting SRC in glioblastoma tumors and brain metastases: Rationale and preclinical studies,” Cancer Letters, vol. 298, no. 2, pp. 139–149, 2010. View at Publisher · View at Google Scholar · View at Scopus
  66. M. Bredel and I. F. Pollack, “The p21-Ras signal transduction pathway and growth regulation in human high-grade gliomas,” Brain Research Reviews, vol. 29, no. 2-3, pp. 232–249, 1999. View at Publisher · View at Google Scholar · View at Scopus
  67. D. Smith, T. Shimamura, S. Barbera, and B. E. Bejcek, “NF-κB controls growth of glioblastomas/astrocytomas,” Molecular and Cellular Biochemistry, vol. 307, no. 1-2, pp. 141–147, 2007. View at Publisher · View at Google Scholar
  68. E. A. Beierle, N. A. Massoll, J. Hartwich et al., “Focal adhesion kinase expression in human neuroblastoma: immunohistochemical and real-time PCR analyses,” Clinical Cancer Research, vol. 14, no. 11, pp. 3299–3305, 2008. View at Publisher · View at Google Scholar · View at Scopus
  69. J. Zhao and J. Guan, “Signal transduction by focal adhesion kinase in cancer,” Cancer and Metastasis Reviews, vol. 28, no. 1-2, pp. 35–49, 2009. View at Publisher · View at Google Scholar · View at Scopus
  70. D. D. Schlaepfer, S. K. Mitra, and D. Ilic, “Control of motile and invasive cell phenotypes by focal adhesion kinase,” Biochimica et Biophysica Acta, vol. 1692, no. 2-3, pp. 77–102, 2004. View at Publisher · View at Google Scholar · View at Scopus
  71. M. Natarajan, T. P. Hecker, and C. L. Gladson, “FAK signaling in anaplastic astrocytoma and glioblastoma tumors,” Cancer Journal, vol. 9, no. 2, pp. 126–133, 2003. View at Publisher · View at Google Scholar · View at Scopus
  72. E.-S. A. Arafa, Q. Zhu, Z. I. Shah et al., “Thymoquinone up-regulates PTEN expression and induces apoptosis in doxorubicin-resistant human breast cancer cells,” Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, vol. 706, no. 1-2, pp. 28–35, 2011. View at Publisher · View at Google Scholar · View at Scopus
  73. G.-G. Mu, L.-L. Zhang, H.-Y. Li, Y. Liao, and H.-G. Yu, “Thymoquinone pretreatment overcomes the insensitivity and potentiates the antitumor effect of gemcitabine through abrogation of notch1, PI3K/Akt/mTOR regulated signaling pathways in pancreatic cancer,” Digestive Diseases and Sciences, vol. 60, no. 4, pp. 1067–1080, 2015. View at Publisher · View at Google Scholar · View at Scopus
  74. S. Rajput, B. N. Kumar, K. K. Dey, I. Pal, A. Parekh, and M. Mandal, “Molecular targeting of Akt by thymoquinone promotes G(1) arrest through translation inhibition of cyclin D1 and induces apoptosis in breast cancer cells,” Life Sciences, vol. 93, pp. 783–790, 2013. View at Publisher · View at Google Scholar
  75. K. M. Sutton, A. L. Greenshields, and D. W. Hoskin, “Thymoquinone, a bioactive component of black caraway seeds, causes G1 phase cell cycle arrest and apoptosis in triple-negative breast cancer cells with mutant p53,” Nutrition and Cancer, vol. 66, no. 3, pp. 408–418, 2014. View at Publisher · View at Google Scholar · View at Scopus
  76. D. Xu, Y. Ma, B. Zhao et al., “Thymoquinone induces G2/M arrest, inactivates PI3K/Akt and nuclear factor-κB pathways in human cholangiocarcinomas both in vitro and in vivo,” Oncology Reports, vol. 31, no. 5, pp. 2063–2070, 2014. View at Publisher · View at Google Scholar · View at Scopus
  77. B. Iskender, K. Izgi, E. Hizar et al., “Inhibition of epithelial-mesenchymal transition in bladder cancer cells via modulation of mTOR signalling,” Tumor Biology, vol. 37, no. 6, pp. 8281–8291, 2016. View at Publisher · View at Google Scholar · View at Scopus
  78. B. Iskender, K. Izgi, and H. Canatan, “Novel anti-cancer agent myrtucommulone-A and thymoquinone abrogate epithelial–mesenchymal transition in cancer cells mainly through the inhibition of PI3K/AKT signalling axis,” Molecular and Cellular Biochemistry, vol. 416, no. 1-2, pp. 71–84, 2016. View at Publisher · View at Google Scholar · View at Scopus
  79. C. El-Baba, V. Mahadevan, F. B. Fahlbusch et al., “Thymoquinone-induced conformational changes of PAK1 interrupt prosurvival MEK-ERK signaling in colorectal cancer,” Molecular Cancer, vol. 13, no. 1, article no. 201, 2014. View at Publisher · View at Google Scholar · View at Scopus
  80. H. Aoki, T. Yokoyama, K. Fujiwara et al., “Phosphorylated Pak1 level in the cytoplasm correlates with shorter survival time in patients with glioblastoma,” Clinical Cancer Research, vol. 13, no. 22, pp. 6603–6609, 2007. View at Publisher · View at Google Scholar · View at Scopus
  81. P. Arumugam, R. Subramanian, J. V. Priyadharsini, and J. Gopalswamy, “Thymoquinone inhibits the migration of mouse neuroblastoma (Neuro-2a) cells by down-regulating MMP-2 and MMP-9,” Chinese Journal of Natural Medicines, vol. 14, no. 12, pp. 904–912, 2016. View at Publisher · View at Google Scholar · View at Scopus
  82. K. Kolli-Bouhafs, A. Boukhari, A. Abusnina et al., “Thymoquinone reduces migration and invasion of human glioblastoma cells associated with FAK, MMP-2 and MMP-9 down-regulation,” Investigational New Drugs, vol. 30, no. 6, pp. 2121–2131, 2012. View at Publisher · View at Google Scholar · View at Scopus
  83. A. Shoieb, M. Elgayyar, P. Dudrick, J. Bell, and P. Tithof, “In vitro inhibition of growth and induction of apoptosis in cancer cell lines by thymoquinone,” International Journal of Oncology, 2003. View at Publisher · View at Google Scholar
  84. S. Darakhshan, A. Bidmeshki Pour, A. Hosseinzadeh Colagar, and S. Sisakhtnezhad, “Thymoquinone and its therapeutic potentials,” Pharmacological Research, vol. 95-96, pp. 138–158, 2015. View at Publisher · View at Google Scholar · View at Scopus
  85. A. O. Kaseb, K. Chinnakannu, D. Chen et al., “Androgen receptor- and E2F-1-targeted thymoquinone therapy for hormone-refractory prostate cancer,” Cancer Research, vol. 67, no. 16, pp. 7782–7788, 2007. View at Publisher · View at Google Scholar · View at Scopus
  86. F. Li, P. Rajendran, and G. Sethi, “Thymoquinone inhibits proliferation, induces apoptosis and chemosensitizes human multiple myeloma cells through suppression of signal transducer and activator of transcription 3 activation pathway,” British Journal of Pharmacology, vol. 161, no. 3, pp. 541–554, 2010. View at Publisher · View at Google Scholar · View at Scopus
  87. M. Alhosin, A. Ibrahim, A. Boukhari et al., “Anti-neoplastic agent thymoquinone induces degradation of α and β tubulin proteins in human cancer cells without affecting their level in normal human fibroblasts,” Investigational New Drugs, vol. 30, no. 5, pp. 1813–1819, 2012. View at Publisher · View at Google Scholar · View at Scopus
  88. A. Paramasivam, S. Sambantham, J. Shabnam et al., “Anti-cancer effects of thymoquinone in mouse neuroblastoma (Neuro-2a) cells through caspase-3 activation with down-regulation of XIAP,” Toxicology Letters, vol. 213, no. 2, pp. 151–159, 2012. View at Publisher · View at Google Scholar · View at Scopus
  89. H. Zubair, H. Y. Khan, A. Sohail et al., “Redox cycling of endogenous copper by thymoquinone leads to ROS-mediated DNA breakage and consequent cell death: Putative anticancer mechanism of antioxidants,” Cell Death & Disease, vol. 4, no. 6, article no. e660, 2013. View at Publisher · View at Google Scholar · View at Scopus
  90. A. R. Hussain, M. Ahmed, S. Ahmed et al., “Thymoquinone suppresses growth and induces apoptosis via generation of reactive oxygen species in primary effusion lymphoma,” Free Radical Biology & Medicine, vol. 50, no. 8, pp. 978–987, 2011. View at Publisher · View at Google Scholar · View at Scopus
  91. T. Fröhlich, B. Ndreshkjana, J. K. Muenzner et al., “Synthesis of Novel Hybrids of Thymoquinone and Artemisinin with High Activity and Selectivity Against Colon Cancer,” ChemMedChem, vol. 12, no. 3, pp. 226–234, 2017. View at Publisher · View at Google Scholar · View at Scopus
  92. G. Sethi, K. S. Ahn, and B. B. Aggarwal, “Targeting nuclear factor-B activation pathway by thymoquinone: role in suppression of antiapoptotic gene products and enhancement of apoptosis,” Molecular Cancer Research, vol. 6, no. 6, pp. 1059–1070, 2008. View at Publisher · View at Google Scholar
  93. A. E. Ashour, A. F. Ahmed, A. Kumar et al., “Thymoquinone inhibits growth of human medulloblastoma cells by inducing oxidative stress and caspase-dependent apoptosis while suppressing NF-κB signaling and IL-8 expression,” Molecular and Cellular Biochemistry, vol. 416, no. 1-2, pp. 141–155, 2016. View at Publisher · View at Google Scholar · View at Scopus
  94. R. L. Gurung, S. N. Lim, A. K. Khaw et al., “Thymoquinone induces telomere shortening, DNA damage and apoptosis in human glioblastoma cells,” PLoS ONE, vol. 5, no. 8, Article ID e12124, 2010. View at Publisher · View at Google Scholar · View at Scopus
  95. A. Kurimasa, S. Kumano, N. V. Boubnov et al., “Requirement for the kinase activity of human DNA-dependent protein kinase catalytic subunit in DNA strand break rejoining,” Molecular and Cellular Biology, vol. 19, no. 5, pp. 3877–3884, 1999. View at Publisher · View at Google Scholar · View at Scopus
  96. G. G. Chen, F. L. F. Sin, B. C. S. Leung, H. K. Ng, and W. S. Poon, “Glioblastoma cells deficient in DNA-dependent protein kinase are resistant to cell death,” Journal of Cellular Physiology, vol. 203, no. 1, pp. 127–132, 2005. View at Publisher · View at Google Scholar · View at Scopus
  97. A. A. Salem, I. A. El Haty, I. M. Abdou, and Y. Mu, “Interaction of human telomeric G-quadruplex DNA with thymoquinone: A possible mechanism for thymoquinone anticancer effect,” Biochimica et Biophysica Acta (BBA) - General Subjects, vol. 1850, no. 2, pp. 329–342, 2015. View at Publisher · View at Google Scholar · View at Scopus
  98. M. Safari and A. Khoshnevisan, “Cancer stem cells and chemoresistance in glioblastoma multiform: A review article,” Journal of Stem Cells, vol. 10, no. 4, pp. 271–285, 2015. View at Google Scholar · View at Scopus
  99. Y. P. Ramirez, J. L. Weatherbee, R. T. Wheelhouse, and A. H. Ross, “Glioblastoma multiforme therapy and mechanisms of resistance,” Pharmaceuticals, vol. 6, no. 12, pp. 1475–1506, 2013. View at Publisher · View at Google Scholar · View at Scopus
  100. S. Bao, Q. Wu, R. E. McLendon et al., “Glioma stem cells promote radioresistance by preferential activation of the DNA damage response,” Nature, vol. 444, no. 7120, pp. 756–760, 2006. View at Publisher · View at Google Scholar · View at Scopus
  101. L. Cheng, Q. Wu, Z. Huang et al., “L1CAM regulates DNA damage checkpoint response of glioblastoma stem cells through NBS1,” EMBO Journal, vol. 30, no. 5, pp. 800–813, 2011. View at Publisher · View at Google Scholar · View at Scopus
  102. G. Liu, “Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma,” Molecular Cancer, vol. 5, p. 67, 2006. View at Publisher · View at Google Scholar
  103. H. Gali-Muhtasib, D. Kuester, C. Mawrin et al., “Thymoquinone triggers inactivation of the stress response pathway sensor CHEK1 and contributes to apoptosis in colorectal cancer cells,” Cancer Research, vol. 68, pp. 5609–5618, 2008. View at Publisher · View at Google Scholar
  104. D. Capper, T. Gaiser, C. Hartmann et al., “Stem-cell-like glioma cells are resistant to TRAIL/Apo2L and exhibit down-regulation of caspase-8 by promoter methylation,” Acta Neuropathologica, vol. 117, no. 4, pp. 445–456, 2009. View at Publisher · View at Google Scholar · View at Scopus
  105. C. Zang, M. Wächter, H. Liu et al., “Ligands for PPARγ and RAR cause induction of growth inhibition and apoptosis in human glioblastomas,” Journal of Neuro-Oncology, vol. 65, no. 2, pp. 107–118, 2003. View at Publisher · View at Google Scholar · View at Scopus
  106. L. Ricci-Vitiani, F. Pedini, C. Mollinari et al., “Absence of caspase 8 and high expression of PED protect primitive neural cells from cell death,” The Journal of Experimental Medicine, vol. 200, no. 10, pp. 1257–1266, 2004. View at Publisher · View at Google Scholar · View at Scopus
  107. C. P. Haar, P. Hebbar, G. C. Wallace IV et al., “Drug resistance in glioblastoma: A mini review,” Neurochemical Research, vol. 37, no. 6, pp. 1192–1200, 2012. View at Publisher · View at Google Scholar · View at Scopus
  108. X. Lei, X. Lv, M. Liu et al., “Thymoquinone inhibits growth and augments 5-fluorouracil-induced apoptosis in gastric cancer cells both in vitro and in vivo,” Biochemical and Biophysical Research Communications, vol. 417, no. 2, pp. 864–868, 2012. View at Publisher · View at Google Scholar · View at Scopus
  109. Y. Kondo, S. Kondo, Y. Tanaka, T. Haqqi, B. P. Barna, and J. K. Cowell, “Inhibition of telomerase increases the susceptibility of human malignant glioblastoma cells to cisplatin-induced apoptosis,” Oncogene, vol. 16, no. 17, pp. 2243–2248, 1998. View at Publisher · View at Google Scholar · View at Scopus
  110. P. Vaupel, D. K. Kelleher, and M. Höckel, “Oxygenation status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy,” Seminars in Oncology, vol. 28, no. 2, supplement 8, pp. 29–35, 2001. View at Publisher · View at Google Scholar · View at Scopus
  111. L. Oliver, C. Olivier, F. Marhuenda, M. Campone, and F. Vallette, “Hypoxia and the Malignant Glioma Microenvironment: Regulation and Implications for Therapy,” Current Molecular Pharmacologye, vol. 2, no. 3, pp. 263–284, 2009. View at Publisher · View at Google Scholar
  112. K. M. Comerford, T. J. Wallace, J. Karhausen, N. A. Louis, M. C. Montalto, and S. P. Colgan, “Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene,” Cancer Research, vol. 62, no. 12, pp. 3387–3394, 2002. View at Google Scholar
  113. M. Tafani, L. Sansone, F. Limana et al., “The interplay of reactive oxygen species, hypoxia, inflammation, and sirtuins in cancer initiation and progression,” Oxidative Medicine and Cellular Longevity, vol. 2016, Article ID 3907147, 2016. View at Publisher · View at Google Scholar · View at Scopus
  114. M. A. Mansour, M. N. Nagi, A. S. El-Khatib, and A. M. Al-Bekairi, “Effects of thymoquinone on antioxidant enzyme activities, lipid peroxidation and dt-diaphorase in different tissues of mice: A possible mechanism of action,” Cell Biochemistry & Function, vol. 20, no. 2, pp. 143–151, 2002. View at Publisher · View at Google Scholar · View at Scopus
  115. I. O. Racoma, W. H. Meisen, Q.-E. Wang, B. Kaur, and A. A. Wani, “Thymoquinone inhibits autophagy and induces cathepsin-mediated, caspase-independent cell death in glioblastoma cells,” PLoS ONE, vol. 8, no. 9, Article ID e72882, 2013. View at Publisher · View at Google Scholar · View at Scopus
  116. X. Fan, W. Matsui, L. Khaki et al., “Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors,” Cancer Research, vol. 66, no. 15, pp. 7445–7452, 2006. View at Publisher · View at Google Scholar · View at Scopus
  117. J. Wang, T. P. Wakeman, J. D. Lathia et al., “Notch promotes radioresistance of glioma stem cells,” Stem Cells, vol. 28, no. 1, pp. 17–28, 2010. View at Publisher · View at Google Scholar · View at Scopus
  118. S. Banerjee, A. O. Kaseb, Z. Wang et al., “Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer,” Cancer Research, vol. 69, pp. 5575–5583, 2009. View at Publisher · View at Google Scholar
  119. J. Sigmond, R. J. Honeywell, T. J. Postma et al., “Gemcitabine uptake in glioblastoma multiforme: Potential as a radiosensitizer,” Annals of Oncology, vol. 20, no. 1, pp. 182–187, 2009. View at Publisher · View at Google Scholar · View at Scopus
  120. P. Zhao, Y.-Z. Zhang, and M.-Z. Sun, “Regulatory effect of small interfering RNA targeting multidrug resistant protein 1 on chemosensitivity of human multiforme glioblastoma cell line BT325,” Aizheng=Chinese journal of cancer, vol. 24, no. 12, pp. 1436–1441, 2005. View at Google Scholar · View at Scopus
  121. T. Tsuruo, M. Naito, A. Tomida et al., “Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal,” Cancer Science, vol. 94, no. 1, pp. 15–21, 2003. View at Publisher · View at Google Scholar · View at Scopus
  122. D. Wang, J. Qiao, X. Zhao, T. Chen, and D. Guan, “Thymoquinone Inhibits IL-1β-Induced Inflammation in Human Osteoarthritis Chondrocytes by Suppressing NF-κB and MAPKs Signaling Pathway,” Inflammation, vol. 38, no. 6, pp. 2235–2241, 2015. View at Publisher · View at Google Scholar · View at Scopus
  123. R. Stupp, W. P. Mason, and M. J. van den Bent, “Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma,” Oncology Times, vol. 27, no. 9, pp. 15-16, 2005. View at Publisher · View at Google Scholar
  124. M. Pazhouhi, R. Sariri, A. Rabzia, and M. Khazaei, “Thymoquinone synergistically potentiates temozolomide cytotoxicity through the inhibition of autophagy in U87MG cell line,” Iranian Journal of Basic Medical Sciences, vol. 19, no. 8, pp. 890–898, 2016. View at Publisher · View at Google Scholar · View at Scopus
  125. G. A. Garden, “Epigenetics and the Modulation of Neuroinflammation,” Neurotherapeutics, vol. 10, no. 4, pp. 782–788, 2013. View at Publisher · View at Google Scholar · View at Scopus
  126. C. L. Mayer, B. R. Huber, and E. Peskind, “Traumatic brain injury, neuroinflammation, and post-traumatic headaches,” Headache: The Journal of Head and Face Pain, vol. 53, no. 9, pp. 1523–1530, 2013. View at Publisher · View at Google Scholar · View at Scopus
  127. W. J. Streit, R. E. Mrak, and W. S. T. Griffin, “Microglia and neuroinflammation: a pathological perspective,” Journal of Neuroinflammation, vol. 1, article 14, 2004. View at Publisher · View at Google Scholar · View at Scopus
  128. S. Razavi, K. E. Lee, B. E. Jin, P. S. Aujla, S. Gholamin, and G. Li, “Immune Evasion Strategies of Glioblastoma,” Frontiers in Surgery, vol. 3, 2016. View at Publisher · View at Google Scholar
  129. N. Kamran et al., “Recent advances and future of immunotherapy for glioblastoma,” Expert Opin Biol Ther, vol. 16, no. 10, pp. 1245–1264, 2016. View at Google Scholar
  130. D. I. Gabrilovich and S. Nagaraj, “Myeloid-derived suppressor cells as regulators of the immune system,” Nature Reviews Immunology, vol. 9, no. 3, pp. 162–174, 2009. View at Publisher · View at Google Scholar · View at Scopus
  131. O. Bloch, C. A. Crane, R. Kaur, M. Safaee, M. J. Rutkowski, and A. T. Parsa, “Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages,” Clinical Cancer Research, vol. 19, no. 12, pp. 3165–3175, 2013. View at Publisher · View at Google Scholar · View at Scopus
  132. J. E. Kim and M. Lim, “The role of checkpoints in the treatment of GBM,” Journal of Neuro-Oncology, vol. 123, no. 3, pp. 413–423, 2015. View at Publisher · View at Google Scholar · View at Scopus
  133. M. Hatano, J. Eguchi, T. Tatsumi et al., “EphA2 as a glioma-associated antigen: a novel target for glioma vaccines,” Neoplasia, vol. 7, no. 8, pp. 717–722, 2005. View at Publisher · View at Google Scholar · View at Scopus
  134. R. M. Prins, X. Wang, H. Soto et al., “Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients,” Journal of Immunotherapy, vol. 36, no. 2, pp. 152–157, 2013. View at Publisher · View at Google Scholar · View at Scopus
  135. D. M. Haynik, A. A. Roma, and R. A. Prayson, “HER-2/neu expression in glioblastoma multiforme,” Applied Immunohistochemistry & Molecular Morphology , vol. 15, no. 1, pp. 56–58, 2007. View at Publisher · View at Google Scholar · View at Scopus
  136. J. H. Sampson et al., “mmunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma,” J Clin Oncol, vol. 31, pp. 4722–4729, 28. View at Google Scholar
  137. M. P. Torres, M. P. Ponnusamy, S. Chakraborty et al., “Effects of thymoquinone in the expression of mucin 4 in pancreatic cancer cells: implications for the development of novel cancer therapies,” Molecular Cancer Therapeutics, vol. 9, no. 5, pp. 1419–1431, 2010. View at Publisher · View at Google Scholar · View at Scopus
  138. K. Palucka and J. Banchereau, “Cancer immunotherapy via dendritic cells,” Nature Reviews Cancer, vol. 12, no. 4, pp. 265–277, 2012. View at Publisher · View at Google Scholar · View at Scopus
  139. D. A. Mitchell, K. A. Batich, M. D. Gunn et al., “Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients,” Nature, vol. 519, no. 7543, pp. 366–369, 2015. View at Publisher · View at Google Scholar · View at Scopus
  140. A.-A. Calinescu, N. Kamran, G. Baker, Y. Mineharu, P. R. Lowenstein, and M. G. Castro, “Overview of current immunotherapeutic strategies for glioma,” Immunotherapy, vol. 7, no. 10, pp. 1073–1104, 2015. View at Publisher · View at Google Scholar · View at Scopus
  141. D. Kirn, T. Hermiston, and F. McCormick, “ONYX-015: Clinical data are encouraging,” Nature Medicine, vol. 4, no. 12, pp. 1341-1342, 1998. View at Publisher · View at Google Scholar · View at Scopus
  142. G. Liu, H. Ying, G. Zeng, C. J. Wheeler, K. L. Black, and J. S. Yu, “HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells,” Cancer Research, vol. 64, no. 14, pp. 4980–4986, 2004. View at Publisher · View at Google Scholar · View at Scopus
  143. N. T. Xuan, E. Shumilina, S. M. Qadri, F. Götz, and F. Lang, “Effect of thymoquinone on mouse dendritic cells,” Cellular Physiology and Biochemistry, vol. 25, no. 2-3, pp. 307–314, 2010. View at Publisher · View at Google Scholar · View at Scopus
  144. W. Yang, M. Bhandaru, V. Pasham et al., “Effect of thymoquinone on cytosolic pH and Na/H+ exchanger activity in mouse dendritic cells,” Cellular Physiology and Biochemistry, vol. 29, no. 1-2, pp. 21–30, 2012. View at Publisher · View at Google Scholar · View at Scopus
  145. Z. Su, M.-F. Tam, D. Jankovic, and M. M. Stevenson, “Vaccination with novel immunostimulatory adjuvants against blood-stage malaria in mice,” Infection and Immunity, vol. 71, no. 9, pp. 5178–5187, 2003. View at Publisher · View at Google Scholar · View at Scopus
  146. L. L. R. Hartman, J. R. Crawford, M. T. Makale et al., “Pediatric phase II trials of poly-ICLC in the management of newly diagnosed and recurrent brain tumors,” Journal of Pediatric Hematology/Oncology, vol. 36, no. 6, pp. 451–457, 2014. View at Publisher · View at Google Scholar · View at Scopus
  147. M. R. Rosenfeld, M. C. Chamberlain, S. A. Grossman et al., “A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma,” Neuro-Oncology, vol. 12, no. 10, pp. 1071–1077, 2010. View at Publisher · View at Google Scholar · View at Scopus
  148. S. R. Amith, P. Jayanth, T. Finlay et al., “Detection of Neu1 Sialidase Activity in Regulating TOLL-like Receptor Activation,” Journal of Visualized Experiments, no. 43, 2010. View at Publisher · View at Google Scholar
  149. T. M. Finlay, P. Jayanth, S. R. Amith et al., “Thymoquinone from nutraceutical black cumin oil activates Neu4 sialidase in live macrophage, dendritic, and normal and type i sialidosis human fibroblast cells via GPCR Gαi proteins and matrix metalloproteinase-9,” Glycoconjugate Journal, vol. 27, no. 3, pp. 329–348, 2010. View at Publisher · View at Google Scholar · View at Scopus
  150. Y. Shan, X. He, W. Song, D. Han, J. Niu, and J. Wang, “Role of IL-6 in the invasiveness and prognosis of glioma,” International Journal of Clinical and Experimental Medicine, vol. 8, no. 6, pp. 9114–9120, 2015. View at Publisher · View at Google Scholar
  151. E. G. Van Meir, “Cytokines and tumors of the central nervous system,” Glia, vol. 15, no. 3, pp. 264–288, 1995. View at Publisher · View at Google Scholar · View at Scopus
  152. D. Lobo-Silva, G. M. Carriche, A. G. Castro, S. Roque, and M. Saraiva, “Balancing the immune response in the brain: IL-10 and its regulation,” Journal of Neuroinflammation, vol. 13, no. 1, article no. 297, 2016. View at Publisher · View at Google Scholar · View at Scopus
  153. K. Strle, “Interleukin-10 in the brain,” Crit Rev Immunol, vol. 21, no. 5, pp. 427–49, 2001. View at Google Scholar
  154. J. Han, C. A. Alvarez-Breckenridge, Q.-E. Wang, and J. Yu, “TGF-beta signaling and its targeting for glioma treatment,” American Journal of Cancer Research, vol. 5, no. 3, pp. 945–955, 2015. View at Google Scholar
  155. I. Tritschler, D. Gramatzki, D. Capper et al., “Modulation of TGF-β activity by latent TGF-β-binding protein 1 in human malignant glioma cells,” International Journal of Cancer, vol. 125, no. 3, pp. 530–540, 2009. View at Publisher · View at Google Scholar · View at Scopus
  156. Y. Lin, G. Zhang, J. Zhang et al., “A panel of four cytokines predicts the prognosis of patients with malignant gliomas,” Journal of Neuro-Oncology, vol. 114, no. 2, pp. 199–208, 2013. View at Publisher · View at Google Scholar · View at Scopus
  157. S. Umar, O. Hedaya, A. K. Singh, and S. Ahmed, “Thymoquinone inhibits TNF-α-induced inflammation and cell adhesion in rheumatoid arthritis synovial fibroblasts by ASK1 regulation,” Toxicology and Applied Pharmacology, vol. 287, no. 3, pp. 299–305, 2015. View at Publisher · View at Google Scholar · View at Scopus
  158. E. Taka, E. A. Mazzio, C. B. Goodman et al., “Anti-inflammatory effects of thymoquinone in activated BV-2 microglial cells,” Journal of Neuroimmunology, vol. 286, pp. 5–12, 2015. View at Publisher · View at Google Scholar · View at Scopus
  159. M. Khazaei and M. Pazhouhi, “Temozolomide-Mediated Apoptotic Death Is Improved by Thymoquinone in U87MG Cell Line,” Cancer Investigation, vol. 35, no. 4, pp. 225–236, 2017. View at Publisher · View at Google Scholar · View at Scopus
  160. E. I. Buchbinder and A. Desai, “CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition,” American Journal of Clinical Oncology, vol. 39, no. 1, pp. 98–106, 2015. View at Publisher · View at Google Scholar
  161. A. Schuessler, C. Smith, L. Beagley et al., “Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma,” Cancer Research, vol. 74, no. 13, pp. 3466–3476, 2014. View at Publisher · View at Google Scholar
  162. M. A. Curran, W. Montalvo, H. Yagita, and J. P. Allison, “PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 107, no. 9, pp. 4275–4280, 2010. View at Publisher · View at Google Scholar · View at Scopus
  163. S. G. M. Piccirillo, B. A. Reynolds, N. Zanetti et al., “Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells,” Nature, vol. 444, no. 7120, pp. 761–765, 2006. View at Publisher · View at Google Scholar · View at Scopus
  164. J. M. Garner, M. Fan, C. H. Yang et al., “Constitutive activation of signal transducer and activator of transcription 3 (STAT3) and nuclear factor κB signaling in glioblastoma cancer stem cells regulates the notch pathway,” The Journal of Biological Chemistry, vol. 288, no. 36, pp. 26167–26176, 2013. View at Publisher · View at Google Scholar · View at Scopus
  165. D. Widera, I. Mikenberg, B. Kaltschmidt, and C. Kaltschmidt, “Potential role of NF-κB in adult neural stem cells: The underrated steersman?” International Journal of Developmental Neuroscience, vol. 24, no. 2-3, pp. 91–102, 2006. View at Publisher · View at Google Scholar · View at Scopus
  166. D. W. Lee, D. Ramakrishnan, J. Valenta, I. F. Parney, K. J. Bayless, and R. Sitcheran, “The NF-κB RelB protein is an oncogenic driver of mesenchymal glioma,” PLoS ONE, vol. 8, no. 2, Article ID e57489, 2013. View at Publisher · View at Google Scholar · View at Scopus
  167. C. Sakalar, M. Yuruk, T. Kaya, M. Aytekin, S. Kuk, and H. Canatan, “Pronounced transcriptional regulation of apoptotic and TNF-NF-kappa-B signaling genes during the course of thymoquinone mediated apoptosis in HeLa cells,” Molecular and Cellular Biochemistry, vol. 383, no. 1-2, pp. 243–251, 2013. View at Publisher · View at Google Scholar · View at Scopus
  168. L. Nogueira, P. Ruiz-Ontañon, A. Vazquez-Barquero et al., “Blockade of the NFκB pathway drives differentiating glioblastoma-initiating cells into senescence both in vitro and in vivo,” Oncogene, vol. 30, no. 32, pp. 3537–3548, 2011. View at Publisher · View at Google Scholar · View at Scopus
  169. Q. Zheng, L. Han, Y. Dong et al., “JAK2/STAT3 targeted therapy suppresses tumor invasion via disruption of the EGFRvIII/JAK2/STAT3 axis and associated focal adhesion in EGFRvIII-expressing glioblastoma,” Neuro-Oncology, vol. 16, no. 9, pp. 1229–1243, 2014. View at Publisher · View at Google Scholar · View at Scopus
  170. O. D. Stechishin, H. A. Luchman, Y. Ruan et al., “On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells,” Neuro-Oncology, vol. 15, no. 2, pp. 198–207, 2013. View at Publisher · View at Google Scholar · View at Scopus
  171. W.-Q. Zhu, J. Wang, X.-F. Guo, Z. Liu, and W.-G. Dong, “Thymoquinone inhibits proliferation in gastric cancer via the STAT3 pathway in vivo and in vitro,” World Journal of Gastroenterology, vol. 22, no. 16, pp. 4149–4159, 2016. View at Publisher · View at Google Scholar · View at Scopus
  172. G. Badr, M. Mohany, and F. Abu-Tarboush, “Thymoquinone decreases F-actin polymerization and the proliferation of human multiple myeloma cells by suppressing STAT3 phosphorylation and Bcl2/Bcl-XL expression,” Lipids in Health and Disease, vol. 10, p. 236, 2011. View at Publisher · View at Google Scholar · View at Scopus
  173. R. Demicheli, M. W. Retsky, W. J. M. Hrushesky, M. Baum, and I. D. Gukas, “The effects of surgery on tumor growth: A century of investigations,” Annals of Oncology, vol. 19, no. 11, pp. 1821–1828, 2008. View at Publisher · View at Google Scholar · View at Scopus
  174. W. Ceelen, P. Pattyn, and M. Mareel, “Surgery, wound healing, and metastasis: recent insights and clinical implications,” Critical Review in Oncology/Hematology, vol. 89, no. 1, pp. 16–26, 2014. View at Publisher · View at Google Scholar · View at Scopus
  175. W. P. Ceelen, S. Morris, P. Paraskeva, and P. Pattyn, “Surgical trauma, minimal residual disease and locoregional cancer recurrence.,” Cancer Treatment and Research, vol. 134, pp. 51–69, 2007. View at Google Scholar · View at Scopus
  176. R. Abramovitch, M. Marikovsky, G. Meir, and M. Neeman, “Stimulation of tumour growth by wound-derived growth factors,” British Journal of Cancer, vol. 79, no. 9-10, pp. 1392–1398, 1999. View at Publisher · View at Google Scholar · View at Scopus
  177. Y. Maniwa, M. Okada, N. Ishii, and K. Kiyooka, “Vascular Endothelial Growth Factor Increased by Pulmonary Surgery Accelerates the Growth of Micrometastases in Metastatic Lung Cancer,” Chest, vol. 114, no. 6, pp. 1668–1675, 1998. View at Publisher · View at Google Scholar · View at Scopus
  178. F. P. K. Wu, K. Hoekman, S. Meijer, and M. A. Cuesta, “VEGF and endostatin levels in wound fluid and plasma after breast surgery,” Angiogenesis, vol. 6, no. 4, pp. 255–257, 2003. View at Publisher · View at Google Scholar · View at Scopus
  179. S. Rajput, B. N. P. Kumar, P. Banik, S. Parida, and M. Mandal, “Thymoquinone restores radiation-induced TGF-β expression and abrogates EMT in chemoradiotherapy of breast cancer cells,” Journal of Cellular Physiology, vol. 230, no. 3, pp. 620–629, 2015. View at Publisher · View at Google Scholar · View at Scopus
  180. T. Yi, S.-G. Cho, Z. Yi et al., “Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways,” Molecular Cancer Therapeutics, vol. 7, no. 7, pp. 1789–1796, 2008. View at Publisher · View at Google Scholar · View at Scopus
  181. I. Ahmad, K. M. Muneer, I. A. Tamimi, M. E. Chang, M. O. Ata, and N. Yusuf, “Thymoquinone suppresses metastasis of melanoma cells by inhibition of NLRP3 inflammasome,” Toxicology and Applied Pharmacology, vol. 270, no. 1, pp. 70–76, 2013. View at Publisher · View at Google Scholar · View at Scopus
  182. J. Kundu, B. Y. Choi, C.-H. Jeong, J. K. Kundu, and K.-S. Chun, “Thymoquinone induces apoptosis in human colon cancer HCT116 cells through inactivation of STAT3 by blocking JAK2- and Src-mediated phosphorylation of EGF receptor tyrosine kinase,” Oncology Reports, vol. 32, no. 2, pp. 821–828, 2014. View at Publisher · View at Google Scholar · View at Scopus
  183. G. Badr, E. A. Lefevre, and M. Mohany, “Thymoquinone inhibits the CXCL12-induced chemotaxis of multiple myeloma cells and increases their susceptibility to fas-mediated apoptosis,” PLoS ONE, vol. 6, no. 9, Article ID e23741, 2011. View at Publisher · View at Google Scholar · View at Scopus
  184. J. Kundu, D.-H. Kim, J. K. Kundu, and K.-S. Chun, “Thymoquinone induces heme oxygenase-1 expression in HaCaT cells via Nrf2/ARE activation: Akt and AMPKα as upstream targets,” Food and Chemical Toxicology, vol. 65, pp. 18–26, 2014. View at Publisher · View at Google Scholar · View at Scopus
  185. M. D. Walker, T. A. Strike, and G. E. Sheline, “An analysis of dose-effect relationship in the radiotherapy of malignant gliomas,” International Journal of Radiation Oncology Biology Physics, vol. 5, no. 10, pp. 1725–1731, 1979. View at Publisher · View at Google Scholar · View at Scopus
  186. G. Delaney, S. Jacob, C. Featherstone, and M. Barton, “The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines,” Cancer, vol. 104, no. 6, pp. 1129–1137, 2005. View at Publisher · View at Google Scholar · View at Scopus
  187. R. Baskar, J. Dai, N. Wenlong, R. Yeo, and K. Yeoh, “Biological response of cancer cells to radiation treatment,” Frontiers in Molecular Biosciences, vol. 1, 2014. View at Publisher · View at Google Scholar
  188. C. Krakstad and M. Chekenya, “Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics,” Molecular Cancer, vol. 9, article 135, 2010. View at Publisher · View at Google Scholar · View at Scopus
  189. K. Kaufmann and G. Thiel, “Epidermal growth factor and platelet-derived growth factor induce expression of Egr-1, a zinc finger transcription factor, in human malignant glioma cells,” Journal of the Neurological Sciences, vol. 189, no. 1-2, pp. 83–91, 2001. View at Publisher · View at Google Scholar · View at Scopus
  190. B. Mukherjee, B. McEllin, C. V. Camacho et al., “EGFRvIII and DNA double-strand break repair: A molecular mechanism for radioresistance in glioblastoma,” Cancer Research, vol. 69, no. 10, pp. 4252–4259, 2009. View at Publisher · View at Google Scholar · View at Scopus
  191. Z. N. Orhon, C. Uzal, M. Kanter, M. Erboga, and M. Demiroglu, “Protective effects of Nigella sativa on gamma radiation-induced jejunal mucosal damage in rats,” Pathology - Research and Practice, vol. 212, no. 5, pp. 437–443, 2016. View at Publisher · View at Google Scholar · View at Scopus
  192. R. Velho-Pereira, A. Kumar, B. N. Pandey, K. P. Mishra, and A. G. Jagtap, “Radioprotection by macerated extract of Nigella sativa in normal tissues of fibrosarcoma bearing mice,” Indian Journal of Pharmaceutical Sciences, vol. 74, no. 5, pp. 403–414, 2012. View at Publisher · View at Google Scholar · View at Scopus
  193. M. S. Guida, A. A. El-Aal, Y. Kafafy, S. F. Salama, B. M. Badr, and G. Badr, “Thymoquinone rescues T lymphocytes from gamma irradiation-induced apoptosis and exhaustion by modulating pro-inflammatory cytokine levels and PD-1, bax, and Bcl-2 signaling,” Cellular Physiology and Biochemistry, vol. 38, no. 2, pp. 786–800, 2016. View at Publisher · View at Google Scholar · View at Scopus
  194. G. R. Stark and J. E. Darnell, “The JAK-STAT pathway at twenty,” Immunity, vol. 36, no. 4, pp. 503–514, 2012. View at Publisher · View at Google Scholar · View at Scopus
  195. H. Yu, D. Pardoll, and R. Jove, “STATs in cancer inflammation and immunity: a leading role for STAT3,” Nature Reviews Cancer, vol. 9, no. 11, pp. 798–809, 2009. View at Publisher · View at Google Scholar · View at Scopus
  196. Y. Xu, Z. Li, C. Zhang, S. Zhang, Y. Ji, and F. Chen, “Knockdown of PKCε Expression Inhibits Growth, Induces Apoptosis and Decreases Invasiveness of Human Glioma Cells Partially Through Stat3,” Journal of Molecular Neuroscience, vol. 55, no. 1, pp. 21–31, 2014. View at Publisher · View at Google Scholar · View at Scopus
  197. M. H. Aziz, B. B. Hafeez, J. M. Sand et al., “Protein kinase Cvarepsilon mediates Stat3Ser727 phosphorylation, Stat3-regulated gene expression, and cell invasion in various human cancer cell lines through integration with MAPK cascade (RAF-1, MEK1/2, and ERK1/2),” Oncogene, vol. 29, no. 21, pp. 3100–3109, 2010. View at Publisher · View at Google Scholar · View at Scopus
  198. T. Peng, L. Zhou, L. Zuo, and Y. Luan, “MIR-506 functions as a tumor suppressor in glioma by targeting STAT3,” Oncology Reports, vol. 35, no. 2, pp. 1057–1064, 2016. View at Publisher · View at Google Scholar · View at Scopus
  199. Ç. Şakalar, K. İzgi, B. İskender et al., “The combination of thymoquinone and paclitaxel shows anti-tumor activity through the interplay with apoptosis network in triple-negative breast cancer,” Tumor Biology, vol. 37, no. 4, pp. 4467–4477, 2016. View at Publisher · View at Google Scholar · View at Scopus
  200. A. M. Schmitt, C. D. Crawley, S. Kang et al., “P50 (NF-κB1) is an effector protein in the cytotoxic response to DNA methylation damage,” Molecular Cell, vol. 44, no. 5, pp. 785–796, 2011. View at Publisher · View at Google Scholar · View at Scopus
  201. G. R. Sareddy, K. Geeviman, C. Ramulu, and P. P. Babu, “The nonsteroidal anti-inflammatory drug celecoxib suppresses the growth and induces apoptosis of human glioblastoma cells via the NF-κB pathway,” Journal of Neuro-Oncology, vol. 106, no. 1, pp. 99–109, 2012. View at Publisher · View at Google Scholar · View at Scopus
  202. K. M. Dhandapani, V. B. Mahesh, and D. W. Brann, “Curcumin suppresses growth and chemoresistance of human glioblastoma cells via AP-1 and NFκB transcription factors,” Journal of Neurochemistry, vol. 102, no. 2, pp. 522–538, 2007. View at Publisher · View at Google Scholar · View at Scopus
  203. D. R. Premkumar, E. P. Jane, N. R. Agostino, J. D. Didomenico, and I. F. Pollack, “Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage,” Molecular Carcinogenesis, vol. 52, no. 2, pp. 118–133, 2013. View at Publisher · View at Google Scholar · View at Scopus
  204. V. Cecarini, L. Quassinti, A. Di Blasio et al., “Effects of thymoquinone on isolated and cellular proteasomes,” FEBS Journal, vol. 277, no. 9, pp. 2128–2141, 2010. View at Publisher · View at Google Scholar · View at Scopus
  205. K. Effenberger, S. Breyer, and R. Schobert, “Terpene conjugates of the Nigella sativa seed-oil constituent thymoquinone with enhanced efficacy in cancer cells,” Chemistry & Biodiversity, vol. 7, no. 1, pp. 129–139, 2010. View at Publisher · View at Google Scholar · View at Scopus
  206. G. M. Ganea, S. O. Fakayode, J. N. Losso, C. F. Van Nostrum, C. M. Sabliov, and I. M. Warner, “Delivery of phytochemical thymoquinone using molecular micelle modified poly(D, L lactide-co-glycolide) (PLGA) nanoparticles,” Nanotechnology, vol. 21, no. 28, Article ID 285104, 2010. View at Publisher · View at Google Scholar · View at Scopus
  207. M. Elmowafy, A. Samy, M. A. Raslan et al., “Enhancement of bioavailability and pharmacodynamic effects of thymoquinone via nanostructured lipid carrier (NLC) formulation,” AAPS PharmSciTech, vol. 17, no. 3, pp. 663–672, 2016. View at Publisher · View at Google Scholar · View at Scopus
  208. E. I. Salim and S. Fukushima, “Chemopreventive potential of volatile oil from black cumin (Nigella sativa L.) seeds against rat colon carcinogenesis,” Nutrition and Cancer, vol. 45, no. 2, pp. 195–202, 2003. View at Publisher · View at Google Scholar · View at Scopus
  209. K. Takano, T. Kojima, T. Keira et al., “A novel drug delivery system for the human nasal epithelium,” Advances in otorhinolaryngology, vol. 77, pp. 67–74, 2016. View at Publisher · View at Google Scholar